Experimental KRRO-110 trial for rare lung condition halted early
NCT ID NCT06677307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called KRRO-110 in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause lung and liver damage. The goal was to check safety and how the drug moves through the body. However, the trial was terminated before completion, so no final conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KRRO-110 (an experimental drug given intravenously)
- What this could lead to
- If successful, KRRO-110 could help control Alpha-1 Antitrypsin Deficiency by raising protective enzyme levels, potentially slowing lung damage.
- What could go wrong
- This early-stage trial was terminated, so results are unknown. The drug is first-in-human, meaning safety and effectiveness are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AATD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
St. Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.